Clay Thorp

This profile gathers the share dealings of Clay Thorp across 3 companies, led by Clearside Biomedical, Inc., Vigil Neuroscience, Inc. and PhaseBio Pharmaceuticals Inc. Over a trading history stretching from 10 February 2021 to 24 February 2025, the count stands at 10 filings.

Market trades split into 6 purchases (€138k) and 1 sale (€120k). The net balance comes to €18k on the buying side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 1 option exercise. 2025 to date brings 1 purchase and no sales.

Half of the purchases are above €17k and half below. On 1 out of 6 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The newest entry dates from 24 February 2025: an open-market purchase of €13k, in Clearside Biomedical, Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.